secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001193125-25-023570
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna adopts amended charter/bylaws with IPO completion; eliminates written consent
--------------------------------------------------------------------------------

- Amended charter authorizes 500M common shares and 10M undesignated preferred shares; prior preferred series removed.
- Stockholder ability to act by written consent or call special meetings eliminated.
- Bylaws updated with advance notice procedures for stockholder proposals and director nominations.
- Changes were previously disclosed in the S-1 and became effective upon January 31, 2025 IPO closing.
- Governance structure now conforms to typical public company standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000119312525023570/0001193125-25-023570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000119312525023570/d886749d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-023570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer